|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||133.16 - 137.59|
|52-week range||105.26 - 153.10|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||33.71|
|Forward dividend & yield||2.89 (2.14%)|
|Ex-dividend date||10 Aug 2023|
|1y target est||N/A|
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, "Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance." Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.